無料セミナー : 2020年3月4日『Future of Immuno-Oncology 免疫腫瘍学の未来』 DelveInsight Business Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

進行腎細胞がん - 疫学予測 2028年

Advanced Renal Cell Carcinoma Epidemiology Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 918175
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.11円で換算しております。
Back to Top
進行腎細胞がん - 疫学予測 2028年 Advanced Renal Cell Carcinoma Epidemiology Forecast - 2028
出版日: 2019年12月01日 ページ情報: 英文 100 Pages
概要

当レポートでは、主要8カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本、中国)の進行腎細胞がん市場について調査し、疾病の概要や現行の治療法、主要8カ国の市場動向、疫学的予測、セグメント別の罹患数の推移と予測をまとめています。

目次

第1章 重要洞察

第2章 疾病背景と概要:進行腎細胞がん

  • イントロダクション
  • 組織学的サブタイプおよび関連分子経路
    • 明細胞腎細胞がん
    • 非明細胞腎細胞がん
  • 腎細胞がんの病理
  • 病態生理
  • 進行腎細胞がんの危険因子
  • 腎細胞がんのメカニズム
  • 腎細胞がんの病期分類
  • 腎細胞がんの遺伝病理学
  • 腎細胞がんのエピジェネティクス
  • 腫瘍の挙動と予後の分子マーカー
  • 腎細胞がんの代謝経路と標的
  • 腎細胞がんにおける免疫系の役割
  • バイオマーカー
    • 分子バイオマーカー
    • 炎症性タンパク質
    • 尿中分子マーカー
  • 診断
  • 診断ガイドライン
    • 腎細胞がんに関する欧州泌尿器科ガイドライン:2019
    • 腎腫瘤および限局性腎がん:AUAガイドライン(2017)
    • 腎細胞がん:診断のためのESMO臨床診療ガイドライン
  • 要約:進行腎細胞がん

第3章 疫学と患者人口

  • 主な調査結果
  • 主要8カ国の進行腎細胞がんの総有病数

第4章 国別の疫学予測

  • 米国
    • 仮定と理論的根拠
    • 腎細胞がんの診断罹患数
    • 腎細胞がんの診断罹患数:性別
    • 腎細胞がんの診断罹患数:病型別
    • 腎細胞がんの診断罹患数:病期別
    • 進行/転移性腎細胞がんの症例数
  • EU5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本
  • 中国

第5章 付録

第6章 DelveInsightのサービス内容

第7章 免責事項

第8章 DelveInsightについて

図表

List of Tables

  • Table 1 Types of Non-clear-cell renal cell carcinomas
  • Table 2 Histological features of papillary urothelial lesions
  • Table 3 Guidelines for the diagnosis of Renal Cell Carcinoma
  • Table 4 Total Diagnosed Incident Population of Advanced Renal Cell Carcinoma (RCC) in the G8 Countries (2017-2028)
  • Table 5 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United States (2017-2028)
  • Table 6 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United States (2017-2028)
  • Table 7 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United States (2017-2028)
  • Table 8 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United States (2017-2028)
  • Table 9 Advanced/Metastatic RCC Total Cases in the United States (2017-2028)
  • Table 10 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Germany (2017-2028)
  • Table 11 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Germany (2017-2028)
  • Table 12 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Germany (2017-2028)
  • Table 13 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Germany (2017-2028)
  • Table 14 Advanced/Metastatic RCC Total Cases in Germany (2017-2028)
  • Table 15 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in France (2017-2028)
  • Table 16 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in France (2017-2028)
  • Table 17 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in France (2017-2028)
  • Table 18 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in France (2017-2028)
  • Table 19 Advanced/Metastatic RCC Total Cases in France (2017-2028)
  • Table 20 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Italy (2017-2028)
  • Table 21 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Italy (2017-2028)
  • Table 22 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Italy (2017-2028)
  • Table 23 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Italy (2017-2028)
  • Table 24 Advanced/Metastatic RCC Total Cases in Italy (2017-2028)
  • Table 25 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Spain (2017-2028)
  • Table 26 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Spain (2017-2028)
  • Table 27 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Spain (2017-2028)
  • Table 28 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Spain (2017-2028)
  • Table 29 Advanced/Metastatic RCC Total Cases in Spain (2017-2028)
  • Table 30 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United Kingdom (2017-2028)
  • Table 31 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United Kingdom (2017-2028)
  • Table 32 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United Kingdom(2017-2028)
  • Table 33 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United Kingdom (2017-2028)
  • Table 34 Advanced/Metastatic RCC Total Cases in the United Kingdom (2017-2028)
  • Table 35 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Japan (2017-2028)
  • Table 36 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Japan (2017-2028)
  • Table 37 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Japan (2017-2028)
  • Table 38 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Japan (2017-2028)
  • Table 39 Advanced/Metastatic RCC Total Cases in Japan (2017-2028)
  • Table 40 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in China (2017-2028)
  • Table 41 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in China (2017-2028)
  • Table 42 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in China (2017-2028)
  • Table 43 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in China (2017-2028)
  • Table 44 Advanced/Metastatic RCC Total Cases in China (2017-2028)

List of Figures

  • Figure 1 VHL inactivation in ccRCC and its implication in targeted therapy
  • Figure 2 Cancer evolution and tumor heterogeneity in ccRCC
  • Figure 3 Von Hippel-Lindau gene (HIF1A and HIF2A are hydroxylated on proline residues and bind the pVHL, resulting in polyubiquitination of HIFA)
  • Figure 4 The mTOR-PI3K pathway.
  • Figure 5 Distinct signaling pathways involved in programmed death 1 (PD-1)/PD-L1 interaction in the tumor microenvironment
  • Figure 6 Cellular and molecular components of the tumor ecosystem that shape the tumor angiogenic landscape.
  • Figure 7 Stages of kidney cancer and recommended treatments
  • Figure 8 Total Diagnosed Incident Patient Population of Advanced Renal Cell Carcinoma (RCC) in the G8 Countries (2017-2028)
  • Figure 9 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United States (2017-2028)
  • Figure 10 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United States (2017-2028)
  • Figure 11 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United States (2017-2028)
  • Figure 12 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United States (2017-2028)
  • Figure 13 Advanced/Metastatic RCC Total Cases in the United States (2017-2028)
  • Figure 14 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Germany (2017-2028)
  • Figure 15 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Germany (2017-2028)
  • Figure 16 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Germany (2017-2028)
  • Figure 17 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Germany (2017-2028)
  • Figure 18 Advanced/Metastatic RCC Total Cases in Germany (2017-2028)
  • Figure 19 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in France (2017-2028)
  • Figure 20 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in France (2017-2028)
  • Figure 21 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in France (2017-2028)
  • Figure 22 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in France (2017-2028)
  • Figure 23 Advanced/Metastatic RCC Total Cases in France (2017-2028)
  • Figure 24 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Italy (2017-2028)
  • Figure 25 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Italy (2017-2028)
  • Figure 26 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Italy (2017-2028)
  • Figure 27 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Italy (2017-2028)
  • Figure 28 Advanced/Metastatic RCC Total Cases in Italy (2017-2028)
  • Figure 29 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Spain (2017-2028)
  • Figure 30 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Spain (2017-2028)
  • Figure 31 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Spain (2017-2028)
  • Figure 32 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Spain (2017-2028)
  • Figure 33 Advanced/Metastatic RCC Total Cases in Spain (2017-2028)
  • Figure 34 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United Kingdom (2017-2028)
  • Figure 35 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United Kingdom (2017-2028)
  • Figure 36 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United Kingdom(2017-2028)
  • Figure 37 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United Kingdom (2017-2028)
  • Figure 38 Advanced/Metastatic RCC Total Cases in the United Kingdom (2017-2028)
  • Figure 39 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Japan (2017-2028)
  • Figure 40 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Japan (2017-2028)
  • Figure 41 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Japan (2017-2028)
  • Figure 42 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Japan (2017-2028)
  • Figure 43 Advanced/Metastatic RCC Total Cases in Japan (2017-2028)
  • Figure 44 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in China (2017-2028)
  • Figure 45 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in China (2017-2028)
  • Figure 46 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in China (2017-2028)
  • Figure 47 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in China (2017-2028)
  • Figure 48 Advanced/Metastatic RCC Total Cases in China (2017-2028)
目次
Product Code: DIEI0398

DelveInsight's 'Advanced Renal Cell Carcinoma Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Advanced Renal Cell Carcinoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
  • China

Study Period: 2017-2028

Advanced Renal Cell Carcinoma Epidemiology

According to the National Organization of Rare Disorders (NORD), renal cell carcinoma accounts for approximately 30,000 new cases of kidney malignancies per year in the United States. It is more common in males than in females (ratio of 2-3:1) and in persons with a history of smoking.

Renal cell carcinomas (RCC) are primary malignant adenocarcinomas derived from the renal tubular epithelium and are the most common malignant renal tumor. They usually occur in 50-70 year old patients and macroscopic hematuria occurs in 60% of the cases.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Advanced Renal Cell Carcinoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028 for the following aspects:

  • Diagnosed Incident Cases of Renal Cell Carcinoma (RCC)
  • Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC)
  • Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC)
  • Stage-specific Diagnosed Incident Cases of RCC
  • Total Cases of Advanced/Metastatic RCC

According to DelveInsight, the total diagnosed incident cases of Advanced Renal Cell Carcinoma in the G8 countries were 69,429 in 2017. In case of total RCC patients in the United States, the diagnosed incident cases were 53,405 in 2017.

Report Scope

  • The report covers the detailed overview of Advanced Renal Cell Carcinoma explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides insight about the historical and forecasted patient pool for G8 countries covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan and China.
  • The report assesses the disease risk and burden and highlights the unmet needs of Advanced Renal Cell Carcinoma.
  • The report helps to recognize the growth opportunities in the G8 countries with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by type-specific cases and severity specific cases of Advanced Renal Cell Carcinoma in the G8 countries.

Key strengths

  • 10-Year Forecast of Advanced Renal Cell Carcinoma epidemiology
  • G8 countries Coverage
  • Total Incident Cases of Advanced Renal Cell Carcinoma
  • Incident Cases according to segmentation

Key assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Note: We understand the needs of the rapidly changing market and DelveInsight's is helping the clients by providing them with the most up to date Report. It usually takes 5-7 days.

Table of Contents

1. Key Insights

2. Disease Background and Overview: Advanced Renal Cell carcinoma

  • 2.1. Introduction
  • 2.2. Histologic Subtypes and Related Molecular Pathways
    • 2.2.1. Clear Cell Renal Cell Carcinoma
    • 2.2.2. Non-clear-cell renal cell carcinomas
  • 2.3. Biology and pathology of renal cell carcinoma
  • 2.4. Pathophysiology
  • 2.5. Risk Factors of Advanced Renal Cell Carcinoma
  • 2.6. Mechanisms of Renal Cell Carcinoma
    • 2.6.1. Genes and pathways
    • 2.6.2. Tumor heterogeneity and cancer evolution
    • 2.6.3. Immune infiltration and the tumor microenvironment
  • 2.7. Staging of renal cell carcinoma
    • 2.7.1. TNM Staging
    • 2.7.2. Composite grading systems for renal carcinoma
    • 2.7.3. Fuhrman Nuclear Grade
  • 2.8. Genetic Pathology of renal cell carcinoma
    • 2.8.1. Von Hippel-Lindau gene
    • 2.8.2. Protein polybromo-1 gene
    • 2.8.3. BRCA1-associated protein-1
    • 2.8.4. The mTOR pathway
  • 2.9. Epigenetics of RCC
  • 2.10. Tumor Behavior and Prognostic Molecular Markers
  • 2.11. Metabolic pathways and targets in renal cell carcinoma
    • 2.11.1. The Glutaminase Pathway
    • 2.11.2. Other metabolic pathways and targets
  • 2.12. Role of the Immune System in Renal Cell Carcinoma
    • 2.12.1. The programmed death-1 receptor (PD-1 receptor) pathway
    • 2.12.2. Interaction between Angiogenesis and the Anti-Tumor Immune Response
  • 2.13. Biomarkers
    • 2.13.1. Molecular biomarkers
    • 2.13.2. Inflammatory Proteins
    • 2.13.3. Molecular Markers in Urine
  • 2.14. Diagnosis
    • 2.14.1. Size, Extent of Invasion Outside of the Kidney
    • 2.14.2. Genomic implications
    • 2.14.3. Histopathological confirmation
    • 2.14.4. Radiologic Evaluation
    • 2.14.5. Screening and Imaging
    • 2.14.6. Preoperative Evaluation
  • 2.15. Diagnostic Guidelines
    • 2.15.1. European Association of Urology Guidelines on Renal Cell Carcinoma: 2019
    • 2.15.2. Renal Mass and Localized Renal Cancer: AUA Guideline (2017)
    • 2.15.3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis
  • 2.16. Nutshell: Advanced Renal Cell Carcinoma

3. Epidemiology and Patient Population

  • 3.1. Key Findings
  • 3.2. G8 Countries Total Diagnosed Incident Patient Population of Advanced Renal Cell Carcinoma (RCC)

4. Country Wise-Epidemiology of Advanced Renal Cell Carcinoma (RCC)

  • 4.1. United States
    • 4.1.1. Assumptions and Rationale
    • 4.1.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United States
    • 4.1.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United States
    • 4.1.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United States
    • 4.1.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United States
    • 4.1.6. Advanced/Metastatic RCC Total Cases in the United States
  • 4.2. EU5 Countries
    • 4.2.1. Assumptions and Rationale
  • 4.3. Germany
    • 4.3.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Germany
    • 4.3.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Germany
    • 4.3.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Germany
    • 4.3.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Germany
    • 4.3.5. Advanced/Metastatic RCC Total Cases in Germany
  • 4.4. France
    • 4.4.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in France
    • 4.4.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in France
    • 4.4.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in France
    • 4.4.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in France
    • 4.4.5. Advanced/Metastatic RCC Total Cases in France
  • 4.5. Italy
    • 4.5.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Italy
    • 4.5.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Italy
    • 4.5.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Italy
    • 4.5.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Italy
    • 4.5.5. Advanced/Metastatic RCC Total Cases in Italy
  • 4.6. Spain
    • 4.6.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Spain
    • 4.6.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Spain
    • 4.6.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Spain
    • 4.6.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Spain
    • 4.6.5. Advanced/Metastatic RCC Total Cases in Spain
  • 4.7. United Kingdom
    • 4.7.1. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United Kingdom
    • 4.7.2. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United Kingdom
    • 4.7.3. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United Kingdom
    • 4.7.4. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United Kingdom
    • 4.7.5. Advanced/Metastatic RCC Total Cases in the United Kingdom
  • 4.8. Japan
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Japan
    • 4.8.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Japan
    • 4.8.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Japan
    • 4.8.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Japan
    • 4.8.6. Advanced/Metastatic RCC Total Cases in Japan
  • 4.9. China
    • 4.9.1. Assumptions and Rationale
    • 4.9.2. Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in China
    • 4.9.3. Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in China
    • 4.9.4. Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in China
    • 4.9.5. Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in China
    • 4.9.6. Advanced/Metastatic RCC Total Cases in China

5. Appendix

  • 5.1. Report Methodology

6. DelveInsight Capabilities

7. Disclaimer

8. About DelveInsight

Back to Top